Docking and scoring: applications to drug discovery in the interactomics era

被引:12
|
作者
Grosdidier, Solene [1 ]
Fernandez-Recio, Juan [1 ]
机构
[1] Barcelona Supercomp Ctr, Dept Life Sci, Barcelona 08034, Spain
关键词
hot-spots; protein-protein docking; protein-protein interactions; virtual ligand screening; PROTEIN-PROTEIN DOCKING; LIGAND BINDING-SITES; HOT-SPOTS; SMALL-MOLECULE; SHAPE COMPLEMENTARITY; ENCOUNTER COMPLEX; ALLOSTERIC MODULATORS; BIOLOGICAL FUNCTION; PEPTIDE INHIBITOR; CYTOKINE-RECEPTOR;
D O I
10.1517/17460440903002067
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Computational approaches such as docking and scoring are becoming routine in drug discovery as a complement to other more traditional techniques. However, so far, computer drug design methods have been applied to inhibit the function of individual proteins, and there is little available data on the use of these computational techniques to target protein-protein interactions. Objective: To establish a strategy for the use of current computational tools in drug discovery targeting protein-protein interactions. Method: Individual techniques applied to specific cases could be studied to derive a general strategy for targeting protein-protein interactions. Conclusion: Protein docking, interface prediction and hot-spot identification can contribute to the discovery of small molecule inhibitors targeting protein interactions of therapeutic interest, especially when little structural information is available.
引用
下载
收藏
页码:673 / 686
页数:14
相关论文
共 50 条
  • [31] Covalent Docking in Drug Discovery: Scope and Limitations
    Scarpino, Andrea
    Ferenczy, Gyorgy G.
    Keseru, Gyorgy M.
    CURRENT PHARMACEUTICAL DESIGN, 2020, 26 (44) : 5684 - 5699
  • [32] Recent advances in dynamic docking for drug discovery
    De Vivo, Marco
    Cavalli, Andrea
    WILEY INTERDISCIPLINARY REVIEWS-COMPUTATIONAL MOLECULAR SCIENCE, 2017, 7 (06)
  • [33] Drug discovery and development in the molecular era
    Dollery, CT
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (01) : 5 - 6
  • [34] Channelopathies and drug discovery in the postgenomic era
    Dayue Darrel Duan
    Tong-hui Ma
    Acta Pharmacologica Sinica, 2011, 32 : 673 - 674
  • [35] Tuberculosis drug discovery in the CRISPR era
    Rock, Jeremy
    PLOS PATHOGENS, 2019, 15 (09)
  • [36] Antibacterial drug discovery in the resistance era
    Eric D. Brown
    Gerard D. Wright
    Nature, 2016, 529 : 336 - 343
  • [37] Channelopathies and drug discovery in the postgenomic era
    Duan, Dayue Darrel
    Ma, Tong-hui
    ACTA PHARMACOLOGICA SINICA, 2011, 32 (06) : 673 - 674
  • [38] Antibacterial drug discovery in the resistance era
    Brown, Eric D.
    Wright, Gerard D.
    NATURE, 2016, 529 (7586) : 336 - 343
  • [39] Drug discovery in big data era
    Okuno, Yasushi
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2016, 130 (03) : S20 - S20
  • [40] Discovery of Plasmepsin Inhibitors by Fragment-Based Docking and Consensus Scoring
    Friedman, Ran
    Caflisch, Amedeo
    CHEMMEDCHEM, 2009, 4 (08) : 1317 - 1326